The clinical data strengthens the case for rese-cel's efficacy and safety across multiple autoimmune indications. Key catalysts to watch: topline registrational DM/ASyS results in 2H27 and BLA submission in 1Q28. Monitor enrollment progress in the registrational SSc-ILD cohort and go-forward strategy for the preconditioning-free approach in 1H27.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $1.50entry
- T+1 · 7d ago −3.33%α −2.97% · $1.45
- T+5 · 20h ago −26.00%α −24.31% · $1.11
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cabaletta Bio presented new Phase 1/2 clinical data for rese-cel at ACR Convergence 2026, showing 100% of dermatomyositis patients maintained immunomodulator-free moderate-to-major TIS responses through one year, 100% of lupus nephritis patients with repeat biopsy achieved DORIS remission and histologic response, and 71% of systemic sclerosis patients achieved rCRISS-50 at one year with a 9% mean FVC improvement in ILD patients. The company also disclosed plans for a BLA submission in myositis in 1Q28 and topline results from the registrational DM/ASyS cohort in 2H27.
Key Facts
- 100% (6/6) of adult DM patients maintained immunomodulator-free moderate-to-major TIS response through one year; 83% (5/6) achieved this at Week 16
- 100% (5/5) of LN patients with repeat kidney biopsy achieved immunomodulator-free DORIS remission and histologic response or remission
- 71% (5/7) of SSc patients achieved immunomodulator-free rCRISS-50 at one year; 5 ILD patients showed 9% mean FVC improvement
- 94% (67/71) of patients had no or Grade 1 CRS; 96% (68/71) had no ICANS; no IEC-HS reported
- Company plans to report topline registrational DM/ASyS results in 2H27 and submit BLA for myositis in 1Q28
- Operational runway into 1Q28 enables all anticipated milestones
Financial Impact
No financial data provided; clinical data supports advancement of registrational cohorts and BLA timeline
Risk Factors
- Phase 1/2 data may not be predictive of registrational trial results
- BLA submission and approval timelines are subject to regulatory review and potential delays
- Competition from other CAR-T and autoimmune therapies could impact commercial adoption
- Manufacturing scale-up and automation (Cellares) carry execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759138-26-000050 |
| Document: caba-20261109.htm | 0001759138-26-000050 |
| Document: caba-ex99_1.htm | 0001759138-26-000050 |
| Document: 0001759138-26-000050-index-headers.html | 0001759138-26-000050 |
| Document: 0001759138-26-000050-index.html | 0001759138-26-000050 |
| Document: 0001759138-26-000050.txt | 0001759138-26-000050 |
Track record
29 reports on CABA
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Viewing Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers